Update on biology and management of mesothelioma
Open Access
- 20 January 2021
- journal article
- research article
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 30 (159) , 200226
Abstract
Malignant pleural mesothelioma is an aggressive, incurable cancer that is usually caused by asbestos exposure several decades before symptoms arise. Despite widespread prohibition of asbestos production and supply, its incidence continues to increase. It is heterogeneous in its presentation and behaviour, and diagnosis can be notoriously difficult. Identification of actionable gene mutations has proven challenging and current treatment options are largely ineffective, with a median survival of 10–12 months.However, the past few years have witnessed major advances in our understanding of the biology and pathogenesis of mesothelioma. This has also revealed the limitations of existing diagnostic algorithms and identified new treatment targets.Recent clinical trials have re-examined the role of surgery, provided new options for the management of associated pleural effusions and heralded the addition of targeted therapies. The increasing complexity of mesothelioma management, along with a desperate need for further research, means that a multidisciplinary team framework is essential for the delivery of contemporary mesothelioma care.This review provides a synthesised overview of the current state of knowledge and an update on the latest research in the field.Keywords
This publication has 107 references indexed in Scilit:
- Dynamics of DNA Damage Induced Pathways to CancerPLOS ONE, 2013
- Recommendations for Uniform Definitions of Surgical Techniques for Malignant Pleural Mesothelioma: A Consensus Report of the International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest GroupJournal of Thoracic Oncology, 2011
- Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility studyThe Lancet Oncology, 2011
- The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesotheliomaNature Genetics, 2011
- Efficacy and Safety of Tunneled Pleural Catheters in Adults with Malignant Pleural Effusions: A Systematic ReviewJournal of General Internal Medicine, 2010
- Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammationProceedings of the National Academy of Sciences, 2010
- Molecular biology of malignant mesotheliomaEnvironmental Health and Preventive Medicine, 2008
- Use of tunnelled catheters for malignant pleural effusions in patients fit for pleurodesisEuropean Respiratory Journal, 2007
- TNF-α inhibits asbestos-induced cytotoxicity via a NF-κB-dependent pathway, a possible mechanism for asbestos-induced oncogenesisProceedings of the National Academy of Sciences, 2006
- Genetic factors in the aetiology of malignant mesotheliomaEuropean Journal of Cancer, 1995